Stock Tip Tuesday - April 23, 2024

$HUMA? Govt Funding?

Stock Tip Tuesday…

Politician Tommy Tuberville Buying up $HUMA

Happy Leonardo Dicaprio GIF by Jordan Belfort

NEWS
Tommy Tuberville May Know Something We Don’t

Last week US Senator Tommy Tuberville was chipping away at $HUMA

Alright, let me break down why this is interesting…

($HUMA) Humacyte is a biotech company developing bio-engineered human tissue that can be used in various medical applications.

They are conducting tests of this tech on Ukrainian Soldiers suffering from combat injuries.

But here is the kicker…

He sits on the Armed Services Committee board which oversees the U.S. military’s operations like budget, expenditures, military research and development, benefits for members of the military, and other aspects of the defense policy.

If you didn’t know, U.S. Congress has directed about $75 billion in assistance to Ukraine…

You see the correlation here? Am I tripping?

So could Tommy Tuberville know something about $HUMA that we don’t?

What we do know is that Humacyte has lobbied over a Million Dollars to obtain favorable policies.

Will the US government be heavily investing in Humacyte?

Well, I sure as hell would not be surprised.

NEWS
$HUMA Performance

Tommy is already up about 25% since his purchase on March 21st.

However, to add to my suspicion of $HUMA gov’t funding, for starters $HUMA has no real catalysts except for their FDA approval which I am unclear on when that was.

They have more debt than cash (115m total liabilities, 80m cash)

No insider or Guru buys, with a ton of insider selling

Bleeding cash (-111m net income), which is expected for a small-cap biotech play, can’t hate too hard there.

So, why is Tommy buying? Does it have something to do with his board seat on the Armed Services Committee and potential government funding for Ukraine Operations?

Only time will tell…

Thank you
That’s All Folks

Thank you for reading. Like usual. Not financial advice. Do your own DD, this is essentially a conspiracy theory, not an Analyst Report. This newsletter doesn’t mean BUY, it’s just a hot take.

We own no stick. Full disclaimer here

Cheers,